alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest studies

Every summary in our library, newest first, as a dated timeline.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 8,076–8,100 of 27,380 studies, newest first · page 324 of 1096.

January 2023 25

  1. 2023 year only

    Dietary Components and Nutritional Strategies for Dementia Prevention in the Elderly

    ✓ Peer-reviewed Prevention and risk Current Alzheimer research

    Key finding: Polyphenols, folate, vitamin D, omega-3 fatty acids, and β-carotene might decrease the risk of dementia. +4 more findings

    Full summary, score breakdown and related studies → Original source

  2. 2023 year only

    Diet's Role in Modifying Risk of Alzheimer's Disease: History and Present Understanding

    ✓ Peer-reviewed Prevention and risk Journal of Alzheimer's disease : JAD

    Key finding: Those studies identified AD risk factors including higher consumption of saturated and total fats, meat, and ultraprocessed foods and a lower risk of AD with higher consumption of fruits, legumes, nuts, omega-3 fatty acids, vegetables, and whole grains. +1 more finding

    Full summary, score breakdown and related studies → Original source

  3. 2023 year only

    Air Pollution and the Risk of Dementia: The Rotterdam Study

    ✓ Peer-reviewed Risk factors Journal of Alzheimer's disease : JAD

    Key finding: Of the 7,511 non-demented participants at baseline, 545 developed dementia during a median follow-up of 7 years. +3 more findings

    Full summary, score breakdown and related studies → Original source

  4. 2023 year only

    Depressive and Biopsychosocial Frailty Phenotypes: Impact on Late-life Cognitive Disorders

    ✓ Peer-reviewed Risk factors Journal of Alzheimer's disease : JAD

    Key finding: Multidimensional frailty phenotypes have been associated with all-cause dementia, mild cognitive impairment (MCI), Alzheimer's disease (AD), AD neuropathology, vascular dementia, and non-AD dementias.

    Full summary, score breakdown and related studies → Original source

  5. 2023 year only

    The Early Stage of Abnormal Aging: Cognitive Impairment

    ✓ Peer-reviewed Risk factors Advances in experimental medicine and biology

    Key finding: Cognitive impairment has become an important aspect affecting the health and quality of life of middle-aged and elderly people, which is defined as the difficulty of thought processing and leads to memory loss, difficulties making decisions, the inability to concentrate, and difficulties learning. +3 more findings

    Full summary, score breakdown and related studies → Original source

  6. 2023 year only

    Cardiovascular Risk Management in Persons with Dementia

    ✓ Peer-reviewed Risk factors Journal of Alzheimer's disease : JAD

    Key finding: However, in this population, beneficial and harmful effects of cardiovascular risk management (CVRM) may be different compared to older persons without cognitive impairment. +2 more findings

    Full summary, score breakdown and related studies → Original source

  7. 2023 year only

    Association Between Sensory Impairment and Dementia: The Roles of Social Network and Leisure Activity

    ✓ Peer-reviewed Risk factors Journal of Alzheimer's disease : JAD

    Key finding: Dual impairment, but not single impairment in hearing and vision was associated with a higher risk of dementia (HR: 1.62, 95% CI: 1.16 to 2.27). +2 more findings

    Full summary, score breakdown and related studies → Original source

  8. 2023 year only

    Understanding the Association Between Sensory Impairment and Dementia: Toward Informing Future Research and Health Policy

    ✓ Peer-reviewed Risk factors Journal of Alzheimer's disease : JAD

    Key finding: Recent epidemiological research has linked decline in multiple sensory functions with an increased risk of dementia.

    Full summary, score breakdown and related studies → Original source

  9. 2023 year only

    Insomnia Symptoms and Biomarkers of Alzheimer's Disease in the Community

    ✓ Peer-reviewed Risk factors Journal of Alzheimer's disease : JAD

    Key finding: Higher ISI score was associated with greater average levels of CSF Aβ42 (per point: 30.7 pg/mL, 95% CI: 4.17-57.3, p = 0.023), as was higher WASO (per 10 min: 136 pg/mL, 95% CI: 48-223, p = 0.002) and more awakenings (per 5:123 pg/mL, 95% CI = 55-192, p < 0.001). +3 more findings

    Full summary, score breakdown and related studies → Original source

  10. 2023 year only

    Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab

    ✓ Peer-reviewed Clinical trials The journal of prevention of Alzheimer's disease

    Key finding: Post-hoc analyses showed that outcomes in the ENGAGE high-dose group were affected by an imbalance in a small number of patients with extremely rapid progression and by lower exposure to the target dose of 10 mg/kg. +3 more findings

    Full summary, score breakdown and related studies → Original source

  11. 2023 year only

    Protocol of a Phase II Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial of S-Adenosyl Methionine in Participants with Mild Cognitive Impairment or Dementia Due to Alzheimer's Disease

    ✓ Peer-reviewed Clinical trials The journal of prevention of Alzheimer's disease

    Key finding: The primary outcome is change in plasma p-tau181 concentration between baseline and following 180 days of treatment, which will be compared between the active and placebo group. +2 more findings

    Full summary, score breakdown and related studies → Original source

  12. 2023 year only

    Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease

    ✓ Peer-reviewed Clinical trials The journal of prevention of Alzheimer's disease

    Key finding: A total of 1795 participants were enrolled (lecanemab:898; placebo:897). +4 more findings

    Full summary, score breakdown and related studies → Original source

  13. 2023 year only

    Foresee Novel Targets for Alzheimer's Disease by Investigating Repurposed Drugs

    ✓ Peer-reviewed Drug development CNS & neurological disorders drug targets

    Key finding: Drugs like Zileuton, Salbutamol, Baricitinib, Carmustine, Paclitaxel, and Nilotinib were observed to be involved in regulation of neurotransmitters. +4 more findings

    Full summary, score breakdown and related studies → Original source

  14. 2023 year only

    The Late Stage of Abnormal Aging: Dementia

    ✓ Peer-reviewed Drug development Advances in experimental medicine and biology

    Key finding: Dementia does not only posing a serious threat to basic daily living in old age but also impose a greater burden on social and medical care as well as the economy. +4 more findings

    Full summary, score breakdown and related studies → Original source

  15. 2023 year only

    Passive tau-based immunotherapy for tauopathies

    ✓ Peer-reviewed Drug development Handbook of clinical neurology

    Key finding: At present, 12 anti-tau antibodies have entered clinical trials, and 7 of them are still in clinical testing for primary tauopathies and AD (semorinemab, bepranemab, E2814, JNJ-63733657, Lu AF87908, PNT00, and APNmAb005). +4 more findings

    Full summary, score breakdown and related studies → Original source

  16. 2023 year only

    Viewpoint: Clinicians' Perspectives on How Disease Modifying Drugs for Alzheimer's Disease Impact Specialty Care

    ✓ Peer-reviewed Treatments The journal of prevention of Alzheimer's disease

    Key finding: In the mid term, the availability of oral anti-amyloid therapy, likely with lower risk of ARIA, may transform clinical practice to a model of screening suitable patients using plasma biomarkers, with a subsequent rapid referral to a specialized memory clinic.

    Full summary, score breakdown and related studies → Original source

  17. 2023 year only

    The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes

    ✓ Peer-reviewed Treatments Journal of Alzheimer's disease : JAD

    Key finding: After the CLARITY-AD clinical trial results of lecanemab were interpreted as positive, and supporting the amyloid hypothesis, the drug received accelerated Food and Drug Administration approval. +1 more finding

    Full summary, score breakdown and related studies → Original source

  18. 2023 year only

    Neuropathology of Anti-Amyloid-β Immunotherapy: A Case Report

    ✓ Peer-reviewed Treatments Journal of Alzheimer's disease : JAD

    Key finding: Neuropathological examination demonstrated histiocytic vasculitis involving blood vessels with cerebral amyloid angiopathy. +1 more finding

    Full summary, score breakdown and related studies → Original source

  19. 2023 year only

    Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review

    ✓ Peer-reviewed Treatments International journal of immunopathology and pharmacology

    Key finding: The FDA approved lecanemab for Alzheimer's disease in January 2023 which acts as a novel disease-modifying anti-amyloid-beta (Aβ) human monoclonal antibody and is administered intravenously. +4 more findings

    Full summary, score breakdown and related studies → Original source

  20. 2023 year only

    Deep Reinforcement Learning-Based Retinal Imaging in Alzheimer's Disease: Potential and Perspectives

    ✓ Peer-reviewed Brain scans and imaging Journal of Alzheimer's disease : JAD

    Key finding: Current retinal imaging demonstrates immense potential as a non-invasive screening measure for AD, by studying qualitative and quantitative changes in the neuronal and vascular structures of the retina that are often associated with degenerative changes in the brain.

    Full summary, score breakdown and related studies → Original source

  21. 2023 year only

    Preclinical Brain Network Abnormalities in Patients with Subjective Cognitive Decline

    ✓ Peer-reviewed Brain scans and imaging Journal of Alzheimer's disease : JAD

    Key finding: No between-group differences in grey matter volumes were detected. +4 more findings

    Full summary, score breakdown and related studies → Original source

  22. 2023 year only

    Chinese Preclinical Alzheimer's Disease Study (C-PAS): Design and Challenge from PET Acceptance

    ✓ Peer-reviewed Brain scans and imaging The journal of prevention of Alzheimer's disease

    Key finding: There were 571 participants in the normal cognition group, 625 participants in the subjective cognitive decline group, 155 participants in the objectively defined subtle cognitive decline group, 501 participants in the mild cognitive impairment group, 471 participants in Alzheimer's disease group, and 128 participants with cognitive impairment from other known causes. +4 more findings

    Full summary, score breakdown and related studies → Original source

  23. 2023 year only

    Hybrid PET/MRI with Flutemetamol and FDG in Alzheimer's Disease Clinical Continuum

    ✓ Peer-reviewed Brain scans and imaging Current Alzheimer research

    Key finding: High Aβ deposition (increased temporal [18F]-Flutemetamol standardized uptake value ratio (SUVr) and centiloid score), low glucose metabolism (decreased temporal lobe and posterior cingulate [18F]-FDG SUVr), low parietal CBF and right hemispheric cortical thickness were independent predictors of low cognitive test performance. +1 more finding

    Full summary, score breakdown and related studies → Original source

  24. 2023 year only

    Weight Loss and Alzheimer's Disease in Down Syndrome

    ✓ Peer-reviewed Brain scans and imaging Journal of Alzheimer's disease : JAD

    Key finding: Polynomial regressions indicated an 0.23 kg/m2 decrease in BMI per year beginning at age 36.5 years, which occurs alongside the period during which Aβ and tau increase and memory and mental status decline. +2 more findings

    Full summary, score breakdown and related studies → Original source

  25. 2023 year only

    [Early-onset familial Alzheimer's disease with spastic paraparesis associated with PSEN1 gene]

    ✓ Peer-reviewed Risk genes beyond APOE Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

    Key finding: In the son examined in 2022 at 27 years old whole-exome sequencing detected a novel PSEN1 missense mutation p.Thr421Ala. +4 more findings

    Full summary, score breakdown and related studies → Original source

Browse the library by subject, with the full score breakdown →